Bruno Bockorny

Jun 13, 2024 | nature.com | Andrea Bullock |Benjamin L. Schlechter |Marwan Fakih |Joseph E. Grossman |Rachel E. Sanborn |Bruno Bockorny | +3 more

AbstractMicrosatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to expand therapy to cold/poorly immunogenic solid tumors, such as MSS mCRC. BOT with or without balstilimab (BAL; anti-PD-1 antibody) is being evaluated in an ongoing expanded phase 1 study.

Mar 28, 2023 | onclive.com | Bruno Bockorny

Bruno B. Bockorny, MD, attending physician, Gastrointestinal Oncology, Beth Israel Deaconess Medical Center; assistant professor, medicine, Harvard Medical School, discusses findings from a phase 1a/b trial (NCT03860272) with the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034) in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.